Tenax Therapeutics, Inc. (TENX)

Over the past six months, Tenax hosted a virtual call with key opinion leaders to discuss the treatment landscape for PH-HFpEF and its Phase 3 TNX-103 program. The company announced the result of a prespecified blinded sample size assessment for the LEVEL study and participated in healthcare conferences. The U.S. Patent and Trademark Office issued a Notice of Allowance for a patent expanding protection for subcutaneous levosimendan. Tenax Therapeutics reported its Fourth Quarter and Full Year 2025 Financial Results and provided a corporate update, which included achieving its randomization target of 230 patients in the Phase 3 LEVEL study, leading to a stock surge. The company announced inducement grants under Nasdaq Listing Rule 5635(c)(4) and the appointment of Timothy Healey as Chief Commercial Officer and Thomas R. Staab, II as Chief Financial Officer.

As a clinical-stage pharmaceutical company, Tenax Therapeutics' primary activities revolve around research and development and conducting clinical trials for its drug candidates. Therefore, traditional demand seasonality is not directly applicable at this stage. The demand for its potential products would be driven by the prevalence of the disease and the lack of approved treatments.

Tenax Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing therapies for cardiovascular and pulmonary diseases, particularly pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF). The company's major product candidates revolve around different formulations of levosimendan, including intravenous (TNX-101), subcutaneous (TNX-102), and oral (TNX-103) formulations. Tenax Therapeutics is also exploring TNX-201 (imatinib) as a potential therapy for pulmonary arterial hypertension (PAH).

Tenax Therapeutics is headquartered in Chapel Hill, North Carolina, United States. The company's clinical development activities, particularly for its lead program TNX-103, have a global reach, with the LEVEL study being conducted in the United States and Canada, and the LEVEL-2 study being a global study with investigative sites across numerous countries.

Tenax Therapeutics' brand reputation is tied to its progress in clinical trials and corporate developments. The company is seen as a promising biopharmaceutical company with a strong focus on addressing unmet medical needs in cardiovascular and pulmonary health. Positive developments have been met with optimism from analysts, and the company's participation in healthcare conferences contributes to its visibility.

As of May 2026, 1.67% of Tenax Therapeutics' stock is owned by institutional investors. The company has 55 institutional owners and shareholders, including Perceptive Advisors LLC, Siren L.L.C., and Millennium Management LLC.